IDEXX Laboratories (IDXX) : Howland Capital Management reduced its stake in IDEXX Laboratories by 0.63% during the most recent quarter end. The investment management company now holds a total of 298,448 shares of IDEXX Laboratories which is valued at $23,795,259 after selling 1,883 shares in IDEXX Laboratories , the firm said in a disclosure report filed with the SEC on Apr 14, 2016.IDEXX Laboratories makes up approximately 2.39% of Howland Capital Management’s portfolio.
IDEXX Laboratories opened for trading at $79.73 and hit $80.345 on the upside on Monday, eventually ending the session at $79.93, with a gain of 0.25% or 0.2 points. The heightened volatility saw the trading volume jump to 9,25,706 shares. Company has a market cap of $7,165 M.
Other Hedge Funds, Including , Acadian Asset Management added IDXX to its portfolio by purchasing 70 company shares during the most recent quarter which is valued at $5,581.Capstone Asset Management Co boosted its stake in IDXX in the latest quarter, The investment management firm added 220 additional shares and now holds a total of 8,642 shares of IDEXX Laboratories which is valued at $689,027. IDEXX Laboratories makes up approx 0.02% of Capstone Asset Management Co’s portfolio.Mai Capital Management boosted its stake in IDXX in the latest quarter, The investment management firm added 14 additional shares and now holds a total of 10,934 shares of IDEXX Laboratories which is valued at $878,328. IDEXX Laboratories makes up approx 0.07% of Mai Capital Management’s portfolio.Creative Planning reduced its stake in IDXX by selling 230 shares or 6.1% in the most recent quarter. The Hedge Fund company now holds 3,540 shares of IDXX which is valued at $284,368. New England Research Management sold out all of its stake in IDXX during the most recent quarter. The investment firm sold 4,050 shares of IDXX which is valued $325,337.
On the company’s financial health, IDEXX Laboratories reported $0.48 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $0.44. The company had revenue of $399.69 million for the quarter, compared to analysts expectations of $396.56 million. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on IDEXX Laboratories. Company shares were Reiterated by Canaccord Genuity on Apr 19, 2016 to “Buy”, Firm has raised the Price Target to $ 85 from a previous price target of $80 .IDEXX Laboratories was Initiated by CL King to “Neutral” on Apr 1, 2016. Company shares were Reiterated by Stifel on Mar 21, 2016 to “Buy”, Firm has raised the Price Target to $ 85 from a previous price target of $80 .
IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.